About CHIGENOVO
CHIGENOVO is a Healthcare company based in China founded in 2016. It operates as a gene therapy drugs for inherited eye diseases are developed. CHIGENOVO has raised $26.45 million across 3 funding rounds from investors including Kunlun Capital, Gimpo Investment and Yingke Capital. CHIGENOVO offers products and services including Gene Therapy Drugs and Gene Diagnosis Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its legal entity in India is εδΊ¬δΈε η§ζζιε ¬εΈ (U99999MH1977PLC010754).
Company details
CHIGENOVO was founded in 2016 and is located in Changping District, China. Operations are centered in the biotechnology sector, where gene therapy drugs for inherited eye diseases are developed alongside genetic diagnosis services. Focus is placed on high-tech advancements to address these conditions through innovative therapeutic and diagnostic approaches. The company operates as a specialized enterprise in this niche.
- Headquarters Changping District, China
- SectorsHealthcare
- Phoneβ’β’β’β’ β’β’β’β’
- Website chigenovo.com
- Legal Name 北京中因科技有限公司
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$26.45M (USD)
in 3 rounds
- InvestorsKunlun Capital
& 6 more
Associated legal entities of CHIGENOVO
CHIGENOVO operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of CHIGENOVO
CHIGENOVO offers a comprehensive portfolio of products and services, including Gene Therapy Drugs and Gene Diagnosis Services.
Gene therapy drugs for hereditary eye diseases are developed and evaluated.
Precise genetic diagnosis for eye diseases is offered through sequencing and analysis.
Funding Insights of CHIGENOVO
CHIGENOVO has successfully raised a total of $26.45M across 3 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $26.45M
- Total Rounds 3
- First Round $10.75M
(Mar 2021)
- Investors Count 7
All 3 funding rounds of CHIGENOVO with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | – | Series A | β | Kunlun Capital | |
| Mar 2022 | $15.7M | Series A | β | β | |
| Mar 2021 | $10.75M | Seed | β | Longmen Capital, Lotus Lake Capital Management | β |
7 investors in total: 7 institutional.
Investors in CHIGENOVO
CHIGENOVO has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Kunlun Capital, Gimpo Investment and Yingke Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in technology companies are managed by Kunlun Capital. | – | kunlun-cap.com | Beijing, China | |
- | – | gimpoinvestment.tcc.mode | - | |
- | – | huayifund.cn | - | |
Venture capital firm focused on mid to early stage companies in hard technology and healthcare sectors | – | juncitouzi.com | Shanghai, China | |
- | – | longmencapital.com | - | |
- | – | tsinghua-vc.com | - | |
Operates as an investment advisory firm providing expert guidance. | 2010 | yingkepe.com | Fuzhou, China |
Investor details for CHIGENOVO
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CHIGENOVO
3 dated milestones of CHIGENOVO across 7 years, from founding to its latest funding, stage changes and deals.
- Founded CHIGENOVO is founded.
- Funding First funding round of $10.7M.
- Funding Latest funding round, Series A,.
Web traffic of CHIGENOVO
The website of CHIGENOVO (chigenovo.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 38.1% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
10 companies that operate in the same segment as CHIGENOVO (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chigenovo
Complete news archive for CHIGENOVO
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CHIGENOVO
CHIGENOVO was founded in 2016 and raised its 1st funding round 5 years after it was founded.
CHIGENOVO is headquartered in China. It is registered at Beijing, China.
CHIGENOVO is a funded company, having raised a total of $26.45M across 3 funding rounds to date. The company's 1st funding round was a Seed of $10.75M, raised on Mar 2021.
CHIGENOVO was founded in 2016 and is located in Changping District, China. Operations are centered in the biotechnology sector, where gene therapy drugs for inherited eye diseases are developed alongside genetic diagnosis services. Focus is placed on high-tech advancements to address these conditions through innovative therapeutic and diagnostic approaches. The company operates as a specialized enterprise in this niche.
CHIGENOVO offers Gene Therapy Drugs and Gene Diagnosis Services.
CHIGENOVO has 7 investors. Key investors include Kunlun Capital, Gimpo Investment, Yingke Capital, Huayi Capital, and Junci Investment.
CHIGENOVO operates through ,.